BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 251] [Article Influence: 35.3] [Reference Citation Analysis]
Number Citing Articles
1 Choi JW, Kim H, Lee J, Yu SJ, Kim YJ, Yoon J, Jae HJ, Hur S, Lee M, Chung JW. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. Eur Radiol 2017;27:1448-58. [DOI: 10.1007/s00330-016-4511-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
2 Delgado TC, Barbier-Torres L, Zubiete-Franco I, Lopitz-Otsoa F, Varela-Rey M, Fernández-Ramos D, Martínez-Chantar ML. Neddylation, a novel paradigm in liver cancer. Transl Gastroenterol Hepatol 2018;3:37. [PMID: 30050997 DOI: 10.21037/tgh.2018.06.05] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
3 Xue F, Liu Y, Zhang H, Wen Y, Yan L, Tang Q, Xiao E, Zhang D. Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression. Onco Targets Ther 2016;9:7253-61. [PMID: 27932893 DOI: 10.2147/OTT.S116127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
4 Aref MH, Aboughaleb IH, Youssef AM, El-Sharkawy YH. Hyperspectral image-based analysis of thermal damage for ex-vivo bovine liver utilizing radiofrequency ablation. Surg Oncol 2021;38:101564. [PMID: 33865183 DOI: 10.1016/j.suronc.2021.101564] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Bai L, Ren Y, Cui T. Overexpression of CDCA5, KIF4A, TPX2, and FOXM1 Coregulated Cell Cycle and Promoted Hepatocellular Carcinoma Development. J Comput Biol 2020;27:965-74. [PMID: 31593490 DOI: 10.1089/cmb.2019.0254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
7 Wei X, Zhao L, Ren R, Ji F, Xue S, Zhang J, Liu Z, Ma Z, Wang XW, Wong L, Liu N, Shi J, Guo X, Roessler S, Zheng X, Ji J. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma. Hepatology 2021;73:1381-98. [PMID: 32609900 DOI: 10.1002/hep.31448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
8 Zhang DZ, Wei XD, Wang XP. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma. World J Gastroenterol 2015; 21(15): 4635-4643 [PMID: 25914473 DOI: 10.3748/wjg.v21.i15.4635] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tang T, Qiu J, Li G, Huang M, Li Y, Li Y, Gu S. Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients. Clinical Radiology 2018;73:259-65. [DOI: 10.1016/j.crad.2017.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
10 Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. Int J Cancer. 2017;140:390-399. [PMID: 27681592 DOI: 10.1002/ijc.30451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Qian K, Ma Y, Wan J, Geng S, Li H, Fu Q, Peng X, Kan X, Zhou G, Liu W, Xiong B, Zhao Y, Zheng C, Yang X, Xu H. The studies about doxorubicin-loaded p(N-isopropyl-acrylamide-co-butyl methylacrylate) temperature-sensitive nanogel dispersions on the application in TACE therapies for rabbit VX2 liver tumor. Journal of Controlled Release 2015;212:41-9. [DOI: 10.1016/j.jconrel.2015.06.013] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
12 He L, Fan X, Li Y, Cui B, Shi Z, Zhou D, Lin H. Aberrant methylation status of SPG20 promoter in hepatocellular carcinoma: A potential tumor metastasis biomarker. Cancer Genet 2019;233-234:48-55. [PMID: 31109594 DOI: 10.1016/j.cancergen.2019.04.003] [Reference Citation Analysis]
13 Yu S, Zhou X, Xiang H, Wang S, Cui Z, Zhou J. Resveratrol Reduced Liver Damage After Liver Resection in a Rat Model by Upregulating Sirtuin 1 (SIRT1) and Inhibiting the Acetylation of High Mobility Group Box 1 (HMGB1). Med Sci Monit 2019;25:3212-20. [PMID: 31041919 DOI: 10.12659/MSM.913937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Lucà MG, Nani R, Schranz M, De Giorgio M, Iegri C, Agazzi R, Sala F, Virotta G, Sarti D, Conte G, Pinelli D, Nicora C, Colledan M, Sironi S, Fagiuoli S. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. Future Oncology 2018;14:727-35. [DOI: 10.2217/fon-2017-0566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Schoenberg MB, Bucher JN, Koch D, Börner N, Hesse S, De Toni EN, Seidensticker M, Angele MK, Klein C, Bazhin AV, Werner J, Guba MO. A novel machine learning algorithm to predict disease free survival after resection of hepatocellular carcinoma. Ann Transl Med 2020;8:434. [PMID: 32395478 DOI: 10.21037/atm.2020.04.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
16 Liu T, Shao Y, Lu L, Shen Y, Hsu C, Lin Z, Hsu C, Cheng A. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2019;13:615-21. [DOI: 10.1080/17474124.2019.1621165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Shang H, Wu B, Liang X, Sun Y, Han X, Zhang L, Wang Q, Cheng W. Evaluation of therapeutic effect of targeting nanobubbles conjugated with NET-1 siRNA by shear wave elastography: an in vivo study of hepatocellular carcinoma bearing mice model. Drug Deliv 2019;26:944-51. [PMID: 31544556 DOI: 10.1080/10717544.2019.1667450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
18 Liu Y, Peng X, Qian K, Ma Y, Wan J, Li H, Zhang H, Zhou G, Xiong B, Zhao Y, Zheng C, Yang X. Temperature sensitive p(N-isopropylacrylamide-co-acrylic acid) modified gold nanoparticles for trans-arterial embolization and angiography. J Mater Chem B 2017;5:907-16. [DOI: 10.1039/c6tb02383e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
19 Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122--a key factor and therapeutic target in liver disease. J Hepatol. 2015;62:448-457. [PMID: 25308172 DOI: 10.1016/j.jhep.2014.10.004] [Cited by in Crossref: 315] [Cited by in F6Publishing: 310] [Article Influence: 45.0] [Reference Citation Analysis]
20 Li W, Li L, Han J, Wu H. Liver transplantation vs liver resection in patients with HBV-related hepatocellular carcinoma beyond Milan criterion: A meta-analysis. Clin Transplant 2018;32:e13193. [PMID: 29315813 DOI: 10.1111/ctr.13193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Mizuhata M, Takamatsu S, Shibata S, Bou S, Sato Y, Kawamura M, Asahi S, Tameshige Y, Maeda Y, Sasaki M, Kumano T, Kobayashi S, Yamamoto K, Tamamura H, Gabata T. Respiratory-gated Proton Beam Therapy for Hepatocellular Carcinoma Adjacent to the Gastrointestinal Tract without Fiducial Markers. Cancers (Basel) 2018;10:E58. [PMID: 29466294 DOI: 10.3390/cancers10020058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
22 Vilgrain V, Van Beers BE, Pastor CM. Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. J Hepatol 2016;64:708-16. [PMID: 26632635 DOI: 10.1016/j.jhep.2015.11.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
23 Li M, Xin Y, Fu S, Liu Z, Li Y, Hu B, Chen S, Liang C, Lu L. Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study. Medicine (Baltimore) 2016;95:e2458. [PMID: 26765441 DOI: 10.1097/MD.0000000000002458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Heidor R, de Conti A, Ortega JF, Furtado KS, Silva RC, Tavares PE, Purgatto E, Ract JN, de Paiva SA, Gioielli LA, Pogribny IP, Moreno FS. The chemopreventive activity of butyrate-containing structured lipids in experimental rat hepatocarcinogenesis. Mol Nutr Food Res 2016;60:420-9. [PMID: 26548572 DOI: 10.1002/mnfr.201500643] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
25 Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017;18:863-872. [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
26 Wang Y, Shang W, Zhong H, Luo T, Niu M, Xu K, Tian J. Tumor Vessel Targeted Self-Assemble Nanoparticles for Amplification and Prediction of the Embolization Effect in Hepatocellular Carcinoma. ACS Nano 2020;14:14907-18. [PMID: 33111520 DOI: 10.1021/acsnano.0c04341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
27 Xu T, Zhang J, Chen W, Pan S, Zhi X, Wen L, Zhou Y, Chen BW, Qiu J, Zhang Y, Yang Q, Feng X, Bai X, Liang T. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial–mesenchymal transition. Cancer Letters 2016;377:140-8. [DOI: 10.1016/j.canlet.2016.04.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
28 Li X, Huang L, Gao W. Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2). Med Sci Monit 2019;25:771-7. [PMID: 30685767 DOI: 10.12659/MSM.910984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
29 Wu G, Ju X, Wang Y, Li Z, Gan X. Up-regulation of SNHG6 activates SERPINH1 expression by competitive binding to miR-139-5p to promote hepatocellular carcinoma progression. Cell Cycle 2019;18:1849-67. [PMID: 31258024 DOI: 10.1080/15384101.2019.1629772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
30 Huang Y, Wang H, Lian Y, Wu X, Zhou L, Wang J, Deng M, Huang Y. Upregulation of kinesin family member 4A enhanced cell proliferation via activation of Akt signaling and predicted a poor prognosis in hepatocellular carcinoma. Cell Death Dis 2018;9:141. [PMID: 29396392 DOI: 10.1038/s41419-017-0114-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
31 Bohlok A, De Grez T, Bouazza F, De Wind R, El-Khoury M, Repullo D, Donckier V. Primary Hepatic Lymphoma Mimicking a Hepatocellular Carcinoma in a Cirrhotic Patient: Case Report and Systematic Review of the Literature. Case Rep Surg 2018;2018:9183717. [PMID: 29850362 DOI: 10.1155/2018/9183717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
32 Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers (Basel) 2021;13:646. [PMID: 33562793 DOI: 10.3390/cancers13040646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
33 Abo-Hashem EM, El-Emshaty WM, Farag Rel S, Zakaria S, Abd El-Aziz M, Ghonaim A. Genetic Polymorphisms of Cytochrome P4501A1 (CYP1A1) and Glutathione S-Transferase P1 (GSTP1) and Risk of Hepatocellular Carcinoma Among Chronic Hepatitis C Patients in Egypt. Biochem Genet 2016;54:696-713. [PMID: 27271262 DOI: 10.1007/s10528-016-9749-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
34 Urakawa H, Kora SI, Mitsufuji T, Osame A, Higahsihara H, Yoshimitsu K. Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population. Acta Radiol 2016;57:1445-52. [PMID: 26861204 DOI: 10.1177/0284185116628339] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Delicque J, Boulin M, Guiu B, Pelage J, Escal L, Schembri V, Assenat E, Fohlen A. Interventional oncology for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2016;40:530-7. [DOI: 10.1016/j.clinre.2016.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
36 Kawaguchi T, Yoshio S, Sakamoto Y, Hashida R, Koya S, Hirota K, Nakano D, Yamamura S, Niizeki T, Matsuse H, Torimura T. Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma. J Clin Med 2020;9:E936. [PMID: 32231160 DOI: 10.3390/jcm9040936] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation. Hepatology. 2016;63:1517-1527. [PMID: 26426978 DOI: 10.1002/hep.28266] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
38 Wang J, Meng J, Ran W, Lee RJ, Teng L, Zhang P, Li Y. Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein. Nano Lett 2019;19:5266-76. [PMID: 31361965 DOI: 10.1021/acs.nanolett.9b01717] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
39 Baffy G. Decoding multifocal hepatocellular carcinoma: an opportune pursuit. Hepatobiliary Surg Nutr 2015;4:206-10. [PMID: 26151061 DOI: 10.3978/j.issn.2304-3881.2014.12.05] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
40 Abbass MA, Ahmad SA, Mahalingam N, Krothapalli KS, Masterson JA, Rao MB, Barthe PG, Mast TD. In vivo ultrasound thermal ablation control using echo decorrelation imaging in rabbit liver and VX2 tumor. PLoS One 2019;14:e0226001. [PMID: 31805129 DOI: 10.1371/journal.pone.0226001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
41 Ardelt MA, Fröhlich T, Martini E, Müller M, Kanitz V, Atzberger C, Cantonati P, Meßner M, Posselt L, Lehr T, Wojtyniak JG, Ulrich M, Arnold GJ, König L, Parazzoli D, Zahler S, Rothenfußer S, Mayr D, Gerbes A, Scita G, Vollmar AM, Pachmayr J. Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy. Hepatology 2019;69:376-93. [PMID: 30033593 DOI: 10.1002/hep.30190] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
42 Savic LJ, Chapiro J, Duwe G, Geschwind JF. Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond? Hepat Oncol 2016;3:19-28. [PMID: 26989470 DOI: 10.2217/hep.15.36] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
43 Huang L, Shen M, Li R, Zhang X, Sun Y, Gao P, Fu H, Liu H, He Y, Du Y, Cao J, Duan Y. Thermo-sensitive composite hydrogels based on poloxamer 407 and alginate and their therapeutic effect in embolization in rabbit VX2 liver tumors. Oncotarget 2016;7:73280-91. [PMID: 27602579 DOI: 10.18632/oncotarget.11789] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
44 Wang D, Wu Q, Guo R, Lu C, Niu M, Rao W. Magnetic liquid metal loaded nano-in-micro spheres as fully flexible theranostic agents for SMART embolization. Nanoscale 2021;13:8817-36. [PMID: 33960346 DOI: 10.1039/d1nr01268a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Lee JH, Yu SJ, Kim YJ, Yoon JH, Cho EJ, Kim SU. Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. Gut Liver 2020;14:477-85. [PMID: 31640304 DOI: 10.5009/gnl19111] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Voglreiter P, Mariappan P, Pollari M, Flanagan R, Blanco Sequeiros R, Portugaller RH, Fütterer J, Schmalstieg D, Kolesnik M, Moche M. RFA Guardian: Comprehensive Simulation of Radiofrequency Ablation Treatment of Liver Tumors. Sci Rep 2018;8:787. [PMID: 29335429 DOI: 10.1038/s41598-017-18899-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
47 Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 2015;4:16-25. [PMID: 26020026 DOI: 10.1159/000343878] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
48 Memeo R, de Blasi V, Cherkaoui Z, Dehlawi A, De' Angelis N, Piardi T, Sommacale D, Marescaux J, Mutter D, Pessaux P. New Approaches in Locoregional Therapies for Hepatocellular Carcinoma. J Gastrointest Cancer 2016;47:239-46. [PMID: 27270711 DOI: 10.1007/s12029-016-9840-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
49 Forner A, Gilabert M, Bruix J, Raoul JL. Intermediate-stage HCC--upfront resection can be feasible. Nat Rev Clin Oncol 2015;12. [PMID: 25850552 DOI: 10.1038/nrclinonc.2014.122-c4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
50 Wu H, Wang MD, Liang L, Xing H, Zhang CW, Shen F, Huang DS, Yang T. Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management. Small 2021;17:e2005236. [PMID: 33448111 DOI: 10.1002/smll.202005236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
52 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
53 Chen YS, Hsieh PM, Lin HY, Hung CM, Lo GH, Hsu YC, Lu IC, Lee CY, Wu TC, Yeh JH, Hsiao P, Li YC, Wang YC, Hsieh KC, Lin CW. Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2021;21:220. [PMID: 33990184 DOI: 10.1186/s12876-021-01807-4] [Reference Citation Analysis]
54 Yuan P, Zheng A, Tang Q. Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway. Cell Biol Int 2020;44:1503-13. [DOI: 10.1002/cbin.11346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
55 Li L, Guo X, Peng X, Zhang H, Liu Y, Li H, He X, Shi D, Xiong B, Zhao Y, Zheng C, Yang X. Radiofrequency-responsive dual-valent gold nanoclusters for enhancing synergistic therapy of tumor ablation and artery embolization. Nano Today 2020;35:100934. [DOI: 10.1016/j.nantod.2020.100934] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
56 Young S, Craig P, Golzarian J. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. Eur Radiol 2019;29:3287-95. [DOI: 10.1007/s00330-018-5782-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
57 Kim H, Bang S, Jee S, Paik SS, Jang K. Clinicopathological significance of CD47 expression in hepatocellular carcinoma. J Clin Pathol 2021;74:111-5. [PMID: 32576628 DOI: 10.1136/jclinpath-2020-206611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Moreno FS, Heidor R, Pogribny IP. Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents. Nutrition and Cancer 2016;68:719-33. [DOI: 10.1080/01635581.2016.1180410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
59 Wan J, Geng S, Zhao H, Peng X, Zhou Q, Li H, He M, Zhao Y, Yang X, Xu H. Doxorubicin-induced co-assembling nanomedicines with temperature-sensitive acidic polymer and their in-situ-forming hydrogels for intratumoral administration. J Control Release 2016;235:328-36. [PMID: 27282415 DOI: 10.1016/j.jconrel.2016.06.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
60 Park J, Kim H, Lee J, Cho E, Kim M, Hur S, Jae HJ, Lee M, Chung JW. Chemoembolisation for hepatocellular carcinoma with bile duct invasion: is preprocedural biliary drainage mandatory? Eur Radiol 2018;28:1540-50. [DOI: 10.1007/s00330-017-5110-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Gabr A, Entezari P, Riaz A, Salem R, Lewandowski RJ. Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. Advances in Clinical Radiology 2020;2:113-25. [DOI: 10.1016/j.yacr.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Shi Y, Zhai B. A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:90-102. [PMID: 27904861 DOI: 10.1159/000445888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
63 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1921] [Article Influence: 707.3] [Reference Citation Analysis]
64 Zhang YF, Zhou J, Wei W, Zou RH, Chen MS, Lau WY, Shi M, Guo RP. Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. Br J Cancer. 2016;115:1039-1047. [PMID: 27701389 DOI: 10.1038/bjc.2016.301] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
65 Lin XH, Qiu BQ, Ma M, Zhang R, Hsu SJ, Liu HH, Chen J, Gao DM, Cui JF, Ren ZG, Chen RX. Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia. Oncogenesis 2020;9:67. [PMID: 32661251 DOI: 10.1038/s41389-020-00251-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
66 Fu Y, Xi M, Pan Y, Chen J, Wang J, Liu S, Xu L, Zhou Z, Liu M, Chen M, Zhao L, Zhang Y. Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. J Oncol 2020;2020:4835653. [PMID: 32565803 DOI: 10.1155/2020/4835653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729244. [PMID: 28975829 DOI: 10.1177/1073274817729244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
68 Gu H, Li J, You N, Wu K, Wang Z, Wang L, Zhu Y, Liu Q, Peng X, Zheng L. Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma. Ann Transl Med 2020;8:1677. [PMID: 33490189 DOI: 10.21037/atm-20-7244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
69 Zhang Z, Tan X, Luo J, Yao H, Si Z, Tong JS. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis 2020;11:902. [PMID: 33097691 DOI: 10.1038/s41419-020-03123-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
70 Wang YH, Liu CL, Chiu WC, Twu YC, Liao YJ. HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1876. [PMID: 31779269 DOI: 10.3390/cancers11121876] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
71 Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011649. [PMID: 28281295 DOI: 10.1002/14651858.cd011649.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
72 Boulin M, Schmitt A, Delhom E, Cercueil JP, Wendremaire M, Imbs DC, Fohlen A, Panaro F, Herrero A, Denys A, Guiu B. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. Eur Radiol. 2016;26:601-609. [PMID: 26060065 DOI: 10.1007/s00330-015-3855-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
73 Li ZL, Yu JJ, Guo JW, Sui CJ, Dai BH, Zhang WG, Chen TH, Li C, Gu WM, Zhou YH, Wang H, Zhang YM, Mao XH, Pawlik TM, Wang MD, Liang L, Wu H, Lau WY, Wu MC, Shen F, Yang T. Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. Eur J Surg Oncol 2019;45:800-7. [PMID: 30594407 DOI: 10.1016/j.ejso.2018.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
74 Zhang W, Tan Y, Jiang L, Yan L, Li B, Wen T, Yang J. Liver resection associated with better outcomes for single large hepatocellular carcinoma located in the same section. Medicine (Baltimore) 2017;96:e6246. [PMID: 28272222 DOI: 10.1097/MD.0000000000006246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
75 Fan X, Deng J, Shi T, Wen H, Li J, Liang Z, Lei F, Liu D, Zhang H, Liang Y, Hao X, Wang Z. Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma. Bioorg Chem 2021;114:105154. [PMID: 34378540 DOI: 10.1016/j.bioorg.2021.105154] [Reference Citation Analysis]
76 Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:598-609. [PMID: 30039640 DOI: 10.1111/apt.14913] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 21.0] [Reference Citation Analysis]
77 Xue Y, Li T, Liu S, Zhu YY, Wang G, Fu L, Chen L. Effects of Triple Effective RNA (teRNA) on the Inhibition of Hepatocellular Carcinoma Cells. J Cancer 2017;8:3903-15. [PMID: 29151979 DOI: 10.7150/jca.20958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Hatanaka T, Kakizaki S, Uehara D, Nagashima T, Ueno T, Namikawa M, Saito S, Hosonuma K, Suzuki H, Naganuma A, Takagi H, Sato K, Uraoka T. Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study. Intern Med 2019;58:1835-44. [PMID: 30918170 DOI: 10.2169/internalmedicine.1594-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
79 Ventura Y, Carr BI, Kori I, Guerra V, Shibolet O. Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization. World J Gastroenterol 2018; 24(15): 1641-1649 [PMID: 29686471 DOI: 10.3748/wjg.v24.i15.1641] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
80 Zhong JH, Torzilli G, Xing H, Li C, Han J, Liang L, Zhang H, Dai SY, Li LQ, Shen F, Yang T. Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clin. 2016;6:125-130. [PMID: 27761414 DOI: 10.1016/j.bbacli.2016.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
81 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
82 Li M, Fu S, Zhu Y, Liu Z, Chen S, Lu L, Liang C. Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma. Oncotarget 2016;7:13248-59. [PMID: 26910890 DOI: 10.18632/oncotarget.7467] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
83 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
84 Torimura T, Iwamoto H. Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. Clin Mol Hepatol 2021;27:236-45. [PMID: 33317248 DOI: 10.3350/cmh.2020.0204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Gill J, Baiceanu A, Clark PJ, Langford A, Latiff J, Yang PM, Yoshida EM, Kanavos P. Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. Future Oncol 2018;14:1701-10. [PMID: 29543521 DOI: 10.2217/fon-2017-0715] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
86 Eso Y, Takai A, Takahashi K, Ueda Y, Taura K, Marusawa H, Seno H. Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E405. [PMID: 30909405 DOI: 10.3390/cancers11030405] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
87 Wei Y, Gu X, Cheng L, Meng F, Storm G, Zhong Z. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Acta Biomaterialia 2019;92:196-204. [DOI: 10.1016/j.actbio.2019.05.034] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
88 Wang H, Du PC, Wu MC, Cong WM. Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. Hepatobiliary Surg Nutr. 2018;7:418-428. [PMID: 30652086 DOI: 10.21037/hbsn.2018.09.05] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
89 Li T, Li M, Hu S, Cheng X, Gao Y, Jiang S, Yu Q, Zhang C, Sun P, Xian W, Song Z, Zhang Y, Zheng Q. MiR-221 mediates the epithelial-mesenchymal transition of hepatocellular carcinoma by targeting AdipoR1. Int J Biol Macromol. 2017;103:1054-1061. [PMID: 28539268 DOI: 10.1016/j.ijbiomac.2017.05.108] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
90 O'Donohoe RL, Kavanagh RG, Cahalane AM, Houlihan DD, McCann JW, Ryan ER. C-arm cone-beam CT parenchymal blood volume imaging for transarterial chemoembolization of hepatocellular carcinoma: implications for treatment planning and response. Eur Radiol Exp 2019;3:21. [PMID: 31144237 DOI: 10.1186/s41747-019-0099-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, Schild HH. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience. Onco Targets Ther 2017;10:4773-85. [PMID: 29033589 DOI: 10.2147/OTT.S137519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
92 Wu J, Chai H, Li F, Ren Q, Gu Y. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma. Life Sci 2020;260:118406. [PMID: 32918976 DOI: 10.1016/j.lfs.2020.118406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
93 Zhong JH, You XM, Lu SD, Wang YY, Xiang BD, Ma L, Wu FX, Yuan WP, Chen Y, Li LQ. Historical Comparison of Overall Survival after Hepatic Resection for Patients With Large and/or Multinodular Hepatocellular Carcinoma. Medicine (Baltimore). 2015;94:e1426. [PMID: 26334902 DOI: 10.1097/md.0000000000001426] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
94 Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol 2016;89:20150943. [PMID: 26943239 DOI: 10.1259/bjr.20150943] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 9.4] [Reference Citation Analysis]
95 Wen P, Chen SD, Wang JR, Zeng YH. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Oncol Res 2019;27:583-92. [PMID: 31053181 DOI: 10.3727/096504018X15368325811545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Ge Y, Shu J, Shi G, Yan F, Li Y, Ding H. miR-100 Suppresses the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells via Targeting CXCR7. J Immunol Res 2021;2021:9920786. [PMID: 34337085 DOI: 10.1155/2021/9920786] [Reference Citation Analysis]
97 Zhou Y, Liang C, Xue F, Chen W, Zhi X, Feng X, Bai X, Liang T. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. Oncotarget 2015;6:10350-65. [PMID: 25871400 DOI: 10.18632/oncotarget.3585] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
98 Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016; 8(14): 607-615 [PMID: 27190577 DOI: 10.4254/wjh.v8.i14.607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
99 Lin WH, Yeh SH, Yeh KH, Chen KW, Cheng YW, Su TH, Jao P, Ni LC, Chen PJ, Chen DS. Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. Proc Natl Acad Sci U S A 2016;113:11937-42. [PMID: 27702890 DOI: 10.1073/pnas.1613466113] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
100 Zhong JH, Pan LH, Wang YY, Cucchetti A, Yang T, You XM, Ma L, Gong WF, Xiang BD, Peng NF, Wu FX, Li LQ. Optimizing stage of single large hepatocellular carcinoma: A study with subgroup analysis by tumor diameter. Medicine (Baltimore) 2017;96:e6608. [PMID: 28403105 DOI: 10.1097/MD.0000000000006608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
101 Yen YH, Cheng YF, Wang JH, Lin CC, Chen CH, Wang CC. Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias. PLoS One 2021;16:e0249194. [PMID: 33765059 DOI: 10.1371/journal.pone.0249194] [Reference Citation Analysis]
102 Wang PC, Hu ZQ, Zhou SL, Zhan H, Zhou ZJ, Luo CB, Huang XW. Downregulation of MAGE family member H1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosis. Future Oncol 2018;14:1177-86. [PMID: 29316827 DOI: 10.2217/fon-2017-0672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
103 Pinato DJ, Arizumi T, Jang JW, Allara E, Suppiah PI, Smirne C, Tait P, Pai M, Grossi G, Kim YW, Pirisi M, Kudo M, Sharma R. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. Oncotarget 2016;7:44705-18. [PMID: 27244889 DOI: 10.18632/oncotarget.9604] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
104 Liu H, Cen D, Yu Y, Wang Y, Liang X, Lin H, Cai X. Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: evidence from the SEER database? BMC Cancer 2018;18:1125. [PMID: 30445928 DOI: 10.1186/s12885-018-4996-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
105 Yuan YL, Yu H, Mu SM, Dong YD, Li Y. MiR-26a-5p Inhibits Cell Proliferation and Enhances Doxorubicin Sensitivity in HCC Cells via Targeting AURKA. Technol Cancer Res Treat 2019;18:1533033819851833. [PMID: 31570091 DOI: 10.1177/1533033819851833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
106 Mafeld S, French J, Tiniakos D, Haugk B, Manas D, Littler P. Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection. Cardiovasc Intervent Radiol 2018;41:816-20. [PMID: 29468286 DOI: 10.1007/s00270-018-1903-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
107 Huang Y, Cheng X, Sun P, Li T, Song Z, Zheng Q. Supplementary Sorafenib Therapies for Hepatocellular Carcinoma-A Systematic Review and Meta-Analysis: Supplementary Sorafenib for Liver Cancer. J Clin Gastroenterol 2019;53:486-94. [PMID: 30939505 DOI: 10.1097/MCG.0000000000001175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Reference Citation Analysis]
109 Cai W, He B, Hu M, Zhang W, Xiao D, Yu H, Song Q, Xiang N, Yang J, He S, Huang Y, Huang W, Jia F, Fang C. A radiomics-based nomogram for the preoperative prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma. Surg Oncol. 2019;28:78-85. [PMID: 30851917 DOI: 10.1016/j.suronc.2018.11.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
110 Ahn SM, Haq F, Park I, Nault JC, Zucman-Rossi J, Yu E. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. BMC Cancer 2018;18:571. [PMID: 29776391 DOI: 10.1186/s12885-018-4192-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
111 McDevitt JL, Collard MD, Murphy RP, Sutphin PD, Yopp AC, Singal AG, Kalva SP. Comparison of radiofrequency and microwave ablation and identification of risk factors for primary treatment failure and local progression. Clin Imaging 2020;67:146-51. [PMID: 32659600 DOI: 10.1016/j.clinimag.2020.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
112 Cucchetti A, Sposito C, Pinna AD, Citterio D, Cescon M, Bongini M, Ercolani G, Cotsoglou C, Maroni L, Mazzaferro V. Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol 2017; 23(8): 1469-1476 [PMID: 28293094 DOI: 10.3748/wjg.v23.i8.1469] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
113 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Cardarelli-Leite L, Hadjivassiliou A, Klass D, Chung J, Ho SGF, Lim HJ, Kim PTW, Mujoomdar A, Liu DM. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Curr Oncol 2020;27:S144-51. [PMID: 33343208 DOI: 10.3747/co.27.7171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
115 Titan AL, Devereaux K, Louie JD, Poultsides GA. Clinical Trigonometry: Right Hepatic Trisegmentectomy After Radiation Trisegmentectomy for Hepatocellular Carcinoma. Dig Dis Sci 2018;63:1419-23. [PMID: 29119415 DOI: 10.1007/s10620-017-4797-2] [Reference Citation Analysis]
116 Zhao H, Xu J, Wan J, Geng S, Li H, Peng X, Fu Q, He M, Zhao Y, Yang X. Cisplatin-directed coordination-crosslinking nanogels with thermo/pH-sensitive triblock polymers: improvement on chemotherapic efficacy via sustained release and drug retention. Nanoscale 2017;9:5859-71. [PMID: 28429810 DOI: 10.1039/c7nr01097d] [Cited by in Crossref: 29] [Cited by in F6Publishing: 3] [Article Influence: 9.7] [Reference Citation Analysis]
117 Fuchs K, Duran R, Denys A, Bize PE, Borchard G, Jordan O. Drug-eluting embolic microspheres for local drug delivery - State of the art. J Control Release 2017;262:127-38. [PMID: 28710006 DOI: 10.1016/j.jconrel.2017.07.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
118 Wu CJ, Tsai YT, Lee IJ, Wu PY, Lu LS, Tsao WS, Huang YJ, Chang CC, Ka SM, Tao MH. Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment. Oncoimmunology. 2018;7:e1477459. [PMID: 30228946 DOI: 10.1080/2162402x.2018.1477459] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
119 Yu M, Li Z. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches. Front Med 2017;11:509-21. [DOI: 10.1007/s11684-017-0546-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
120 Ribeiro de Souza A, Reig M, Bruix J. Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy 2016;17:1923-36. [DOI: 10.1080/14656566.2016.1225722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
121 Chen RX, Gan YH, Ge NL, Chen Y, Ma M, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG. A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. J Cancer 2019;10:6535-42. [PMID: 31777583 DOI: 10.7150/jca.34064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Mantry PS, Mehta A, Madani B, Mejia A, Shahin I. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol 2017;8:799-807. [PMID: 29184683 DOI: 10.21037/jgo.2017.08.03] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
123 Boulin M, Delhom E, Pierredon-foulongne M, Cercueil J, Guiu B. Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day. Diagnostic and Interventional Imaging 2015;96:607-15. [DOI: 10.1016/j.diii.2015.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
124 Shen L, Zeng Q, Guo P, Huang J, Li C, Pan T, Chang B, Wu N, Yang L, Chen Q, Huang T, Li W, Wu P. Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data. Nat Commun 2018;9:2230. [PMID: 29884785 DOI: 10.1038/s41467-018-04633-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
125 Van Thai N, Thinh NT, Ky TD, Bang MH, Giang DT, Ha LN, Son MH, Tien DD, Lee HW. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma. BMC Gastroenterol 2021;21:216. [PMID: 33980171 DOI: 10.1186/s12876-021-01805-6] [Reference Citation Analysis]
126 Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract 2017;71:e12972. [DOI: 10.1111/ijcp.12972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
127 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 110] [Article Influence: 19.7] [Reference Citation Analysis]
128 Boix L, López-Oliva JM, Rhodes AC, Bruix J. Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF-β pathway. Oncotarget 2016;7:71309-29. [PMID: 27612430 DOI: 10.18632/oncotarget.11885] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
129 Jeganathan S, Budziszewski E, Bielecki P, Kolios MC, Exner AA. In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors. J Control Release 2020;324:146-55. [PMID: 32389777 DOI: 10.1016/j.jconrel.2020.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Chen Y, Huang F, Deng L, Yuan X, Tao Q, Wang T, Li D, Fan Y, Peng Q, Tang D. HIF-1-miR-219-SMC4 Regulatory Pathway Promoting Proliferation and Migration of HCC under Hypoxic Condition. Biomed Res Int 2019;2019:8983704. [PMID: 31828143 DOI: 10.1155/2019/8983704] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
131 Hu M, Li M, Huang H, Lu C. Isolated cancer stem cells from human liver cancer: morphological and functional characteristics in primary culture. Clin Transl Oncol 2021. [PMID: 34169442 DOI: 10.1007/s12094-021-02667-w] [Reference Citation Analysis]
132 Lin CW, Chen YS, Lo GH, Hsu YC, Hsu CC, Wu TC, Yeh JH, Hsiao P, Hsieh PM, Lin HY, Shu CW, Hung CM. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2020;20:99. [PMID: 32272898 DOI: 10.1186/s12876-020-01235-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
133 Sun JY, Yin T, Zhang XY, Lu XJ. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol 2019;234:12116-21. [PMID: 30648254 DOI: 10.1002/jcp.28019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
134 Lanza E, Donadon M, Felisaz P, Mimmo A, Chiti A, Torzilli G, Balzarini L, Lopci E. Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion. Nuclear Medicine Communications 2017;38:826-36. [DOI: 10.1097/mnm.0000000000000719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
135 Vouche M, Degrez T, Bouazza F, Delatte P, Galdon MG, Hendlisz A, Flamen P, Donckier V. Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma. World J Hepatol 2017; 9(36): 1372-1377 [PMID: 29359022 DOI: 10.4254/wjh.v9.i36.1372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
136 Martin AN, Wilkins LR, Das D, Johnston LE, Bauer TW, Adams RB, Zaydfudim VM. Efficacy of Radiofrequency Ablation versus Transarterial Chemoembolization for Patients with Solitary Hepatocellular Carcinoma ≤3 cm. The American Surgeon 2019;85:150-5. [DOI: 10.1177/000313481908500220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
137 Wang ZX, Li J, Wang EX, Xia DD, Bai W, Wang QH, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. World J Gastroenterol 2020; 26(15): 1805-1819 [PMID: 32351295 DOI: 10.3748/wjg.v26.i15.1805] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Goda Y, Morimoto M, Irie K, Kobayashi S, Ueno M, Moriya S, Tezuka S, Ohkawa S, Morinaga S, Numata K, Tanaka K, Maeda S. Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study. Japanese Journal of Clinical Oncology 2017;47:1151-6. [DOI: 10.1093/jjco/hyx131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Tat Trung N, Duong DC, Tong HV, Hien TTT, Hoan PQ, Bang MH, Binh MT, Ky TD, Tung NL, Thinh NT, Sang VV, Thao LTP, Bock CT, Velavan TP, Meyer CG, Song LH, Toan NL. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma. PLoS One 2018;13:e0196081. [PMID: 29672637 DOI: 10.1371/journal.pone.0196081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
140 Zai W, Chen W, Han Y, Wu Z, Fan J, Zhang X, Luan J, Tang S, Jin X, Fu X, Gao H, Ju D, Liu H. Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma. Carcinogenesis 2020;41:345-57. [PMID: 31175354 DOI: 10.1093/carcin/bgz104] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
141 Fako V, Martin SP, Pomyen Y, Budhu A, Chaisaingmongkol J, Franck S, Lee JM, Ng IO, Cheung TT, Wei X, Liu N, Ji J, Zhao L, Liu Z, Jia HL, Tang ZY, Qin LX, Kloeckner R, Marquardt J, Greten T, Wang XW. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. Int J Biol Sci 2019;15:2654-63. [PMID: 31754337 DOI: 10.7150/ijbs.39534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
142 Song Q, Ren W, Fan L, Zhao M, Mao L, Jiang S, Zhao C, Cui Y. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection. Dig Dis Sci 2020;65:1266-75. [PMID: 31312995 DOI: 10.1007/s10620-019-05733-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
143 Garancini M, Pinotti E, Nespoli S, Romano F, Gianotti L, Giardini V. Hepatic resection beyond barcelona clinic liver cancer indication: When and how. World J Hepatol 2016; 8(11): 513-519 [PMID: 27099652 DOI: 10.4254/wjh.v8.i11.513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
144 Barman PM, Su GL. Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2016;7:32-35. [PMID: 31041024 DOI: 10.1002/cld.530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
145 Tak KY, Jang B, Lee SK, Nam HC, Sung PS, Bae SH, Choi JY, Yoon SK, Jang JW. Use of M2BPGi in HCC patients with TACE. J Gastroenterol Hepatol 2021. [PMID: 34031909 DOI: 10.1111/jgh.15553] [Reference Citation Analysis]
146 Liu C, Xu D, Xue B, Liu B, Li J, Huang J. Upregulation of RUNX1 Suppresses Proliferation and Migration through Repressing VEGFA Expression in Hepatocellular Carcinoma. Pathol Oncol Res 2020;26:1301-11. [PMID: 31289995 DOI: 10.1007/s12253-019-00694-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
147 Cao L, Cheng H, Jiang Q, Li H, Wu Z. APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Aging (Albany NY). 2020;12:4573-4591. [PMID: 32167932 DOI: 10.18632/aging.102913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
148 Qu S, Zhang X, Wu Y, Li H, Zhai J, Wu D. miR-361-3p Regulates Liver Tumor-initiating Cells Expansion and Chemo-resistance. J Cancer 2021;12:1483-92. [PMID: 33531993 DOI: 10.7150/jca.52395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
149 Wu B, Cui J, Yang XM, Liu ZY, Song F, Li L, Jiang JL, Chen ZN. Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy. Cell Death Dis. 2017;8:e2925. [PMID: 28703811 DOI: 10.1038/cddis.2017.251] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
150 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Reference Citation Analysis]
151 Bettinger D, Spode R, Glaser N, Buettner N, Boettler T, Neumann-Haefelin C, Brunner TB, Gkika E, Maruschke L, Thimme R, Schultheiss M. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterol 2017;17:98. [PMID: 28797231 DOI: 10.1186/s12876-017-0656-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
152 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 981] [Article Influence: 526.7] [Reference Citation Analysis]
153 Cai XR, Chen ZH, Liu MM, Lin JX, Zhang XP, Chen J, Lin Q, Ma XK, Wen JY, Xie SD, Wu XY, Dong M. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer. 2018;9:2380-2388. [PMID: 30026834 DOI: 10.7150/jca.22925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
154 Li J, Huang L, Yan J, Qiu M, Yan Y. Liver resection for hepatocellular carcinoma: personal experiences in a series of 1330 consecutive cases in China. ANZ J Surg 2018;88:E713-7. [PMID: 29363237 DOI: 10.1111/ans.14381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
155 Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncol Rep. 2016;36:613-625. [PMID: 27278244 DOI: 10.3892/or.2016.4842] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
156 Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90 [PMID: 28144389 DOI: 10.4254/wjh.v9.i2.80] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
157 Kikuchi L, Chagas AL, Alencar RSSM, Tani C, Diniz MA, D'Albuquerque LAC, Carrilho FJ. Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. Clinics (Sao Paulo) 2017;72:454-60. [PMID: 28954003 DOI: 10.6061/clinics/2017(08)01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
158 Guo H, Wu T, Lu Q, Li M, Guo JY, Shen Y, Wu Z, Nan KJ, Lv Y, Zhang XF. Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages. Cancer Manag Res 2018;10:361-9. [PMID: 29503583 DOI: 10.2147/CMAR.S152707] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
159 Chen S, Jin H, Dai Z, Wei M, Xiao H, Su T, Li B, Liu X, Wang Y, Li J, Shen S, Zhou Q, Peng B, Peng Z, Peng S. Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma. Cancer Med 2019;8:1530-9. [PMID: 30864247 DOI: 10.1002/cam4.2038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
160 Zhou Y, Chen E, Tang Y, Mao J, Shen J, Zheng X, Xie S, Zhang S, Wu Y, Liu H, Zhi X, Ma T, Ni H, Chen J, Chai K, Chen W. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis 2019;10:843. [PMID: 31695022 DOI: 10.1038/s41419-019-2053-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 18.0] [Reference Citation Analysis]
161 Yin J, Wang X, Sun X, Dai H, Song X, Li B, Zhang Y, Chen P, Dong X. Thrombin Based Photothermal-Responsive Nanoplatform for Tumor-Specific Embolization Therapy. Small 2021;:e2105033. [PMID: 34729905 DOI: 10.1002/smll.202105033] [Reference Citation Analysis]
162 Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World J Gastroenterol 2017; 23(18): 3195-3204 [PMID: 28566879 DOI: 10.3748/wjg.v23.i18.3195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
163 Di Sandro S, Centonze L, Pinotti E, Lauterio A, De Carlis R, Romano F, Gianotti L, De Carlis L; The NTF Research Group. Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases. Updates Surg 2019;71:285-93. [DOI: 10.1007/s13304-019-00649-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
164 Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Cai BB, Shi KQ, Li P, Chen BC, Shi L, Johnson PJ, Lai P, Toyoda H, Zhou MT. A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection. Clin Chim Acta 2018;485:187-94. [PMID: 29908940 DOI: 10.1016/j.cca.2018.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
166 Wang Y, Ji C, Wang Y, Ji M, Yang J, Zhou C. Predicting postoperative liver cancer death outcomes with machine learning. Current Medical Research and Opinion 2021;37:629-34. [DOI: 10.1080/03007995.2021.1885361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Lei JY, Zhong JJ, Yan LN, Zhu JQ, Wang WT, Zeng Y, Li B, Wen TF, Yang JY; -Liver Surgery Group. Response to transarterial chemoembolization as a selection criterion for resection of hepatocellular carcinomas. Br J Surg. 2016;103:881-890. [PMID: 27027978 DOI: 10.1002/bjs.9864] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
168 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
169 Zaydfudim VM, Vachharajani N, Klintmalm GB, Jarnagin WR, Hemming AW, Doyle MB, Cavaness KM, Chapman WC, Nagorney DM. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg 2016;264:650-8. [PMID: 27433910 DOI: 10.1097/SLA.0000000000001866] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
170 Lemaire M, Lucidi V, Bouazza F, Katsanos G, Vanderlinden B, Levillain H, Delatte P, Garcia CA, Vouche M, Galdon MG, Demetter P, Deleporte A, Hendlisz A, Flamen P, Donckier V. Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study. HPB 2018;20:641-8. [DOI: 10.1016/j.hpb.2018.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
171 Jonczyk M, Collettini F, Geisel D, Schnapauff D, Böning G, Wieners G, Gebauer G. Radiation exposure during TACE procedures using additional cone-beam CT (CBCT) for guidance: safety and precautions. Acta Radiol 2018;59:1277-84. [DOI: 10.1177/0284185118761203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
172 Wu X, Chapiro J, Malhotra A, Kothary N. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. J Vasc Interv Radiol 2021;32:2-12.e1. [PMID: 33160827 DOI: 10.1016/j.jvir.2020.09.022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Chu H, Wu C, Zhao Q, Sun R, Yang K, Zhao B, Liu Y, Liang Z, Zhong S, Zhang L, Zhang Y. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells. Carcinogenesis 2021;42:753-61. [PMID: 33677528 DOI: 10.1093/carcin/bgab019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Ji G, Ma L, Yao H, Ma S, Si X, Wang Y, Bao X, Ma L, Chen F, Ma C, Huang L, Fang X, Song W. Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. Acta Pharm Sin B 2020;10:2171-82. [PMID: 33304784 DOI: 10.1016/j.apsb.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
175 Chen P, Yuan P, Chen B, Sun J, Shen H, Qian Y. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:75-85. [PMID: 27350573 DOI: 10.1016/j.clinre.2016.05.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
176 Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, Zhou G, Zhou J, Zhang X, Ji W, Yu Z, Li T, Zhu D, Hu W, Ji J, Du H, Shi C, Guo X, Fang J, Han J, Gu W, Xie X, Sun Z, Xu H, Wu X, Hu T, Huang J, Hu H, Zheng J, Luo J, Chen Y, Yu W, Shao G. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. Oncol Res 2020;28:249-71. [PMID: 31856933 DOI: 10.3727/096504019X15766663541105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
177 Pinato DJ, Murray SM, Forner A, Kaneko T, Fessas P, Toniutto P, Mínguez B, Cacciato V, Avellini C, Diaz A, Boyton RJ, Altmann DM, Goldin RD, Akarca AU, Marafioti T, Mauri FA, Casagrande E, Grillo F, Giannini E, Bhoori S, Mazzaferro V. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer 2021;9:e003311. [PMID: 34593621 DOI: 10.1136/jitc-2021-003311] [Reference Citation Analysis]
178 Liu J, Cui X, Qu L, Hua L, Wu M, Shen Z, Lu C, Ni R. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma. Exp Mol Pathol 2016;101:58-65. [PMID: 27302463 DOI: 10.1016/j.yexmp.2016.06.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
179 Wang X, Gong Y, Deng T, Zhang L, Liao X, Han C, Yang C, Huang J, Wang Q, Song X, Zhang T, Yu T, Zhu G, Ye X, Peng T. Diagnostic and prognostic significance of mRNA expressions of apolipoprotein A and C family genes in hepatitis B virus-related hepatocellular carcinoma. J Cell Biochem 2019;120:18246-65. [PMID: 31211449 DOI: 10.1002/jcb.29131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
180 Xu L, Gao H, Huang J, Wang H, Zhou Z, Zhang Y, Li S, Chen M. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol 2015;30:1032-9. [PMID: 25639513 DOI: 10.1111/jgh.12910] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
181 Li T, Xue Y, Wang G, Gu T, Li Y, Zhu YY, Chen L. Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma. J Cancer 2016;7:1317-27. [PMID: 27390607 DOI: 10.7150/jca.15157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
182 Zweerink S, Mesghenna S, Mueck V, Schulte S, Kuetting F, Quaas A, Goeser T, Nierhoff D. First evaluation of Neighbor of Punc E11 (NOPE) as a novel marker in human hepatocellular carcinoma. Cancer Biomark 2021;30:75-83. [PMID: 32986656 DOI: 10.3233/CBM-190819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017;67:173-83. [DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 17.3] [Reference Citation Analysis]
184 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
185 Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Gao Q, Wang XY, Zhou J, Fan J. Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol. 2015;12:10. [PMID: 25421283 DOI: 10.1038/nrclinonc.2014.122-c1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
187 Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
188 de la Torre MA, Buades-Mateu J, de la Rosa PA, Lué A, Bustamante FJ, Serrano MT, Testillano M, Lorente S, Arenas JI, Gil C, Iñarrairaegui M, Sangro B. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int 2016;36:1206-12. [PMID: 26910784 DOI: 10.1111/liv.13098] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
189 Wang W, Yang X, Li C, Li Y, Wang H, Han X. Immunogenic Cell Death (ICD) of Murine H22 Cells Induced by Lentinan. Nutr Cancer 2021;:1-10. [PMID: 33715541 DOI: 10.1080/01635581.2021.1897632] [Reference Citation Analysis]
190 Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D, Wang K, Xia Y, Shen F. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget 2016;7:83806-16. [PMID: 27566566 DOI: 10.18632/oncotarget.11514] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
191 Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36. [PMID: 30447470 DOI: 10.1016/j.ctrv.2018.11.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 24.0] [Reference Citation Analysis]
192 Chen J, Zheng DX, Yu XJ, Sun HW, Xu YT, Zhang YJ, Xu J. Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients. Oncoimmunology 2019;8:e1652540. [PMID: 31646099 DOI: 10.1080/2162402X.2019.1652540] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
193 Zhang YF, Shi M, Lu LH, Wang L, Guo RP. Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. J Hepatocell Carcinoma 2021;8:253-61. [PMID: 33907695 DOI: 10.2147/JHC.S305581] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Tomonari T, Takeishi S, Taniguchi T, Tanaka T, Tanaka H, Fujimoto S, Kimura T, Okamoto K, Miyamoto H, Muguruma N, Takayama T. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Oncotarget 2016;7:7207-15. [PMID: 26769852 DOI: 10.18632/oncotarget.6889] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
195 Rekik S, Guyot E, Bhais M, Ajavon Y, Grando V, Bourcier V, Nkontchou G, Nahon P, Sellier N, Seror O, Ganne-Carrie N, Nault JC. The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization. Dig Liver Dis 2016;48:1088-92. [PMID: 27375209 DOI: 10.1016/j.dld.2016.06.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
196 Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E8165. [PMID: 33142892 DOI: 10.3390/ijms21218165] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
197 Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. The Lancet Oncology 2017;18:e101-12. [DOI: 10.1016/s1470-2045(16)30569-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 15.5] [Reference Citation Analysis]
198 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
199 Yang Y, Zhang J, Wu T, Xu X, Cao G, Li H, Chen X. Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1. Life Sci 2019;216:200-6. [PMID: 30465789 DOI: 10.1016/j.lfs.2018.11.043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
200 Liu Z, Bi Y, Sun Y, Hao F, Lu J, Meng Q, Lee RJ, Tian Y, Xie J. Pharmacokinetics of a liposomal formulation of doxorubicin in rats. Saudi Pharm J 2017;25:531-6. [PMID: 28579888 DOI: 10.1016/j.jsps.2017.04.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
201 He Y, Yuan T, Wang X, Shen M, Ding L, Huang L, Wang S, Kong P, Zhou X, Duan Y, Cao J. Temperature sensitive hydrogel for preoperative treatment of renal carcinoma. Mater Sci Eng C Mater Biol Appl 2020;111:110798. [PMID: 32279747 DOI: 10.1016/j.msec.2020.110798] [Reference Citation Analysis]
202 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 156.2] [Reference Citation Analysis]
203 Zeng J, Li L, Zhang H, Li J, Liu L, Zhou G, Du Q, Zheng C, Yang X. Radiopaque and uniform alginate microspheres loaded with tantalum nanoparticles for real-time imaging during transcatheter arterial embolization. Theranostics 2018;8:4591-600. [PMID: 30279724 DOI: 10.7150/thno.27379] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
204 Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Kulik L, Master F, Salem R. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Res Protoc 2018;7:e11234. [PMID: 30111528 DOI: 10.2196/11234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
205 Forner A, Gilabert M, Bruix J, Raoul JL. Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol 2015;12:10. [PMID: 25421282 DOI: 10.1038/nrclinonc.2014.122-c2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
206 Burk KS, Singh AK, Vagefi PA, Sahani D. Pretransplantation Imaging Workup of the Liver Donor and Recipient. Radiologic Clinics of North America 2016;54:185-97. [DOI: 10.1016/j.rcl.2015.09.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
207 Wang X, Liao X, Yu T, Gong Y, Zhang L, Huang J, Yang C, Han C, Yu L, Zhu G, Qin W, Liu Z, Zhou X, Liu J, Han Q, Peng T. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma. Int J Oncol 2019;55:805-22. [PMID: 31485610 DOI: 10.3892/ijo.2019.4862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
208 Glantzounis GK, Paliouras A, Stylianidi MC, Milionis H, Tzimas P, Roukos D, Pentheroudakis G, Felekouras E. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. Eur J Surg Oncol. 2018;44:195-208. [PMID: 29258719 DOI: 10.1016/j.ejso.2017.11.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
209 Jiao HK, Xu Y, Li J, Wang W, Mei Z, Long XD, Chen GQ. Prognostic significance of Cbx4 expression and its beneficial effect for transarterial chemoembolization in hepatocellular carcinoma. Cell Death Dis 2015;6:e1689. [PMID: 25766328 DOI: 10.1038/cddis.2015.57] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
210 Sun YD, Zhang H, Chen YQ, Wu CX, Zhang JB, Xu HR, Liu JZ, Han JJ. HMGB1, the Next Predictor of Transcatheter Arterial Chemoembolization for Liver Metastasis of Colorectal Cancer? Front Oncol 2020;10:572418. [PMID: 33473353 DOI: 10.3389/fonc.2020.572418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017;67:999-1008. [PMID: 28687477 DOI: 10.1016/j.jhep.2017.06.026] [Cited by in Crossref: 234] [Cited by in F6Publishing: 229] [Article Influence: 58.5] [Reference Citation Analysis]
212 Xie Y, Tian H, Xiang B, Zhang Y, Liu J, Cai Z, Xiang H. Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes. Medicine (Baltimore) 2021;100:e26958. [PMID: 34414963 DOI: 10.1097/MD.0000000000026958] [Reference Citation Analysis]
213 Srinivas C, Swathi V, Priyanka C, Anjana Devi T, Subba Reddy BV, Janaki Ramaiah M, Bhadra U, Bhadra MP. Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma. Apoptosis 2016;21:1249-64. [DOI: 10.1007/s10495-016-1278-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
214 Zhou T, Liang X, Wang P, Hu Y, Qi Y, Jin Y, Du Y, Fang C, Tian J. A Hepatocellular Carcinoma Targeting Nanostrategy with Hypoxia-Ameliorating and Photothermal Abilities that, Combined with Immunotherapy, Inhibits Metastasis and Recurrence. ACS Nano 2020;14:12679-96. [DOI: 10.1021/acsnano.0c01453] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
215 Zhao X, Liu X, Zhang P, Liu Y, Ran W, Cai Y, Wang J, Zhai Y, Wang G, Ding Y, Li Y. Injectable peptide hydrogel as intraperitoneal triptolide depot for the treatment of orthotopic hepatocellular carcinoma. Acta Pharm Sin B 2019;9:1050-60. [PMID: 31649853 DOI: 10.1016/j.apsb.2019.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
216 Lian Y, Fan W, Huang Y, Wang H, Wang J, Zhou L, Wu X, Deng M, Huang Y. Downregulated Trophinin-Associated Protein Plays a Critical Role in Human Hepatocellular Carcinoma Through Upregulation of Tumor Cell Growth and Migration. Oncol Res 2018;26:691-701. [PMID: 29117881 DOI: 10.3727/096504017X15101398724809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
217 Wei W, Yang Z, Lu L, Li J, Lei Z, Wang K, Xia Y, Yan Z, Shen F. Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma. International Journal of Surgery 2018;56:256-63. [DOI: 10.1016/j.ijsu.2018.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
218 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
219 Swersky A, Kulik L, Kalyan A, Grace K, Caicedo JC, Lewandowski RJ, Salem R. Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Semin Intervent Radiol 2021;38:432-7. [PMID: 34629710 DOI: 10.1055/s-0041-1735528] [Reference Citation Analysis]
220 Mohnike K, Steffen IG, Seidensticker M, Hass P, Damm R, Peters N, Seidensticker R, Schütte K, Arend J, Bornschein J, Streitparth T, Wybranski C, Wieners G, Stübs P, Malfertheiner P, Pech M, Ricke J. Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. Cardiovasc Intervent Radiol 2019;42:239-49. [DOI: 10.1007/s00270-018-2127-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
221 Xie Q, Chen Z, Xia L, Zhao Q, Yu H, Yang Z. Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population. Gene. 2018;674:188-194. [PMID: 29940275 DOI: 10.1016/j.gene.2018.06.069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
222 Zheng J, Shen S, Jiang L, Yan L, Yang J, Li B, Wen T, Wang W, Xu M. Outcomes of anterior approach major hepatectomy with diaphragmatic resection for single huge right lobe HCC with diaphragmatic invasion. Medicine (Baltimore) 2018;97:e12194. [PMID: 30200125 DOI: 10.1097/MD.0000000000012194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
223 Lee TY, Lin CC, Chen CY, Wang TE, Lo GH, Chang CS, Chao Y. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial. Medicine (Baltimore). 2017;96:e7655. [PMID: 28906355 DOI: 10.1097/md.0000000000007655] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
224 Zhong J, Lu S, Wang Y, Ma L, Li L. Intermediate-stage HCC—upfront resection can be feasible. Nat Rev Clin Oncol 2015;12:295-295. [DOI: 10.1038/nrclinonc.2014.122-c3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
225 Wang T, Sun F, Xie W, Tang M, He H, Jia X, Tian X, Wang M, Zhang J. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Cancer Lett 2016;372:166-78. [PMID: 26791237 DOI: 10.1016/j.canlet.2016.01.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
226 Sayan M, Yegya-Raman N, Greco SH, Gui B, Zhang A, Chundury A, Grandhi MS, Hochster HS, Kennedy TJ, Langan RC, Malhotra U, Rustgi VK, Shah MM, Spencer KR, Carpizo DR, Nosher JL, Jabbour SK. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Front Oncol 2019;9:345. [PMID: 31275846 DOI: 10.3389/fonc.2019.00345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
227 Fang X, Shen A. Preparation and evaluation of phytantriol liquid crystal as a liquid embolic agent. Pharm Dev Technol 2020;25:610-6. [PMID: 32008407 DOI: 10.1080/10837450.2020.1725046] [Reference Citation Analysis]
228 Li Y, Ye Y, Feng B, Qi Y. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway. J Cell Biochem. 2017;118:4498-4507. [PMID: 28464252 DOI: 10.1002/jcb.26107] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 17.3] [Reference Citation Analysis]
229 Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study. Liver Cancer 2020;9:308-25. [PMID: 32647633 DOI: 10.1159/000505692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
230 Deng L, Yang C, Li LQ, Zhong JH. Hepatic Resection Improves Long-Term Survival of Patients with Large and/or Multinodular Hepatocellular Carcinoma. J Gastrointest Surg 2015;19:2288-9. [PMID: 26464016 DOI: 10.1007/s11605-015-2965-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
231 Biolato M, Gallusi G, Iavarone M, Cabibbo G, Racco S, Santis AD, Corte CD, Maida M, Attili AF, Sangiovanni A, Cammà C, La Torre G, Gasbarrini A, Grieco A. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology 2018;17:110-8. [DOI: 10.5604/01.3001.0010.7542] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
232 Aref MH, Aboughaleb IH, El-sharkawy YH. Tissue characterization utilizing hyperspectral imaging for liver thermal ablation. Photodiagnosis and Photodynamic Therapy 2020;31:101899. [DOI: 10.1016/j.pdpdt.2020.101899] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
233 Jonczyk M, Chapiro J, Collettini F, Geisel D, Schnapauff D, Streitparth F, Schmidt T, Hamm B, Gebauer B, Wieners G. Diagnostic Accuracy of Split-Bolus Single-Phase Contrast-Enhanced Cone-Beam CT for the Detection of Liver Tumors before Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology 2017;28:1378-85. [DOI: 10.1016/j.jvir.2017.05.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
234 Brar G, Kesselman A, Malhotra A, Shah MA. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncol Pract 2021;:OP2100227. [PMID: 34255552 DOI: 10.1200/OP.21.00227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Thompson SM, Wells ML, Andrews JC, Ehman EC, Menias CO, Hallemeier CL, Roberts LR, Venkatesh SK. Venous invasion by hepatic tumors: imaging appearance and implications for management. Abdom Radiol (NY) 2018;43:1947-67. [PMID: 28929197 DOI: 10.1007/s00261-017-1298-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
236 Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018;24:219-24. [PMID: 29792289 DOI: 10.5152/dir.2018.17528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
237 Pinato DJ, Brown MW, Trousil S, Aboagye EO, Beaumont J, Zhang H, Coley HM, Mauri FA, Sharma R. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. Br J Cancer 2019;120:512-21. [PMID: 30765873 DOI: 10.1038/s41416-018-0373-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
238 Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Reference Citation Analysis]
239 Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, Liang PC, Santos-Ocampo RS, Lo RH, Lim KB, Tai DW, Ng DC, Irani FG, Gogna A, Chow PK. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol 2016;12:1193-204. [PMID: 27007495 DOI: 10.2217/fon-2016-0035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
240 Herath NI, Devun F, Herbette A, Lienafa M, Chouteau P, Sun J, Dutreix M, Denys A. Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models. Eur Radiol 2017;27:4435-44. [DOI: 10.1007/s00330-017-4792-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
241 Yuan D, Chen Y, Li X, Li J, Zhao Y, Shen J, Du F, Kaboli PJ, Li M, Wu X, Ji H, Cho CH, Wen Q, Li W, Xiao Z, Chen B. Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis. Int J Biol Sci 2021;17:220-35. [PMID: 33390845 DOI: 10.7150/ijbs.50730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
242 Chen D, Zou J, Zhao Z, Tang X, Deng Z, Jia J, Liu S. TXNDC9 promotes hepatocellular carcinoma progression by positive regulation of MYC-mediated transcriptional network. Cell Death Dis 2018;9:1110. [PMID: 30382079 DOI: 10.1038/s41419-018-1150-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
243 Luo Y, Wang X, Ma L, Ma Z, Li S, Fang X, Ma X. Bioinformatics analyses and biological function of lncRNA ZFPM2-AS1 and ZFPM2 gene in hepatocellular carcinoma. Oncol Lett 2020;19:3677-86. [PMID: 32382322 DOI: 10.3892/ol.2020.11485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Pan J, Wang F, Ye L. Doxorubicin-induced epithelial–mesenchymal transition through SEMA 4A in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2016;479:610-4. [DOI: 10.1016/j.bbrc.2016.09.167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
245 Nitta H, Allard MA, Sebagh M, Karam V, Ciacio O, Pittau G, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Bismuth H, Guettier C, Samuel D, Baba H, Adam R. Predictive model for microvascular invasion of hepatocellular carcinoma among candidates for either hepatic resection or liver transplantation. Surgery 2019;165:1168-75. [PMID: 30878140 DOI: 10.1016/j.surg.2019.01.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
246 Li X, Yu H, Huang Y, Chen Y, Wang J, Xu L, Zhang F, Zhuge Y, Zou X. Preparation of microspheres encapsulating sorafenib and catalase and their application in rabbit VX2 liver tumor. Biomed Pharmacother 2020;129:110512. [PMID: 32768982 DOI: 10.1016/j.biopha.2020.110512] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Lu SD, Wang YY, Peng NF, Peng YC, Zhong JH, Qin HG, Xiang BD, You XM, Ma L, Li LQ. Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma. Medicine (Baltimore) 2016;95:e2722. [PMID: 26844516 DOI: 10.1097/MD.0000000000002722] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
248 Gao X, Jiang Y, Li Y. Inhibitory effect of miR-140-5p on doxorubicin resistance of hepatocellular carcinoma. Exp Ther Med 2021;21:507. [PMID: 33791016 DOI: 10.3892/etm.2021.9938] [Reference Citation Analysis]
249 Ou HY, Wu YN, Yu CY, Chen CL, Hsu HW, Weng CC, Leung-Chit Tsang L, Huang TL, Tong YS, Lim WX, Cheng YF. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up. J Vasc Interv Radiol 2020;31:1784-91. [PMID: 33023805 DOI: 10.1016/j.jvir.2020.06.009] [Reference Citation Analysis]
250 Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019;28:228-235. [PMID: 30851906 DOI: 10.1016/j.suronc.2019.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
251 Mokdad AA, Zhu H, Marrero JA, Mansour JC, Singal AG, Yopp AC. Hospital Volume and Survival After Hepatocellular Carcinoma Diagnosis. American Journal of Gastroenterology 2016;111:967-75. [DOI: 10.1038/ajg.2016.181] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]